Moderately Hypofractionated Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: A New Way Forward for Dose Escalation?

Despite extensive investigation of alternatives, the standard treatment for locally advanced non-small cell lung cancer (LA-NSCLC) remains chemoradiation therapy (CRT) to 60 Gy. Recently, the addition of consolidation immunotherapy after CRT has been shown to significantly improve survival; however, despite this significant advancement, only 43% of patients are expected to remain alive at 5 years.1 In-field recurrences remain an important driver of morbidity and mortality, afflicting approximately 40% of patients.